Quintiles has relocated its Global Central Lab in Japan from Saitama to Tokyo to allow for further expansion. The new facility has expanded testing capabilities with an initial focus on safety testing. The lab started receiving and testing clinical trial samples and has received National Glycohemoglobin Standardization Program Level 1 certification for diabetes testing. Additionally, the new Japan lab is working towards certification by the College of American Pathologists (CAP).

“The growth of clinical research in Asia-Pacific is driving this move as we continue to reduce complexity and help our customers get new medicines to patients faster,” said Alan Ong, vice president and general manager, Quintiles Global Central Laboratories Asia. “We are building on a strong record of high quality and outstanding customer service, and with an expanding test menu, it makes sense to move into new facilities that provide room for growth.”